These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 24375669)
1. Nizatidine ameliorates gastroparesis in Parkinson's disease: a pilot study. Doi H; Sakakibara R; Sato M; Hirai S; Masaka T; Kishi M; Tsuyusaki Y; Tateno A; Tateno F; Takahashi O; Ogata T Mov Disord; 2014 Apr; 29(4):562-6. PubMed ID: 24375669 [TBL] [Abstract][Full Text] [Related]
2. Dietary herb extract rikkunshi-to ameliorates gastroparesis in Parkinson's disease: a pilot study. Doi H; Sakakibara R; Sato M; Hirai S; Masaka T; Kishi M; Tsuyusaki Y; Tateno A; Tateno F; Takahashi O; Ogata T Eur Neurol; 2014; 71(3-4):193-5. PubMed ID: 24457529 [TBL] [Abstract][Full Text] [Related]
3. Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying. Futagami S; Shimpuku M; Song JM; Kodaka Y; Yamawaki H; Nagoya H; Shindo T; Kawagoe T; Horie A; Gudis K; Iwakiri K; Sakamoto C Digestion; 2012; 86(2):114-21. PubMed ID: 22846371 [TBL] [Abstract][Full Text] [Related]
4. Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. Doi H; Sakakibara R; Sato M; Masaka T; Kishi M; Tateno A; Tateno F; Tsuyusaki Y; Takahashi O J Neurol Sci; 2012 Aug; 319(1-2):86-8. PubMed ID: 22632782 [TBL] [Abstract][Full Text] [Related]
5. Nizatidine ameliorates slow transit constipation in Parkinson's disease. Sakakibara R; Doi H; Sato M; Hirai S; Masaka T; Kishi M; Tsuyusaki Y; Tateno A; Tateno F; Aiba Y; Ogata T; Suzuki Y J Am Geriatr Soc; 2015 Feb; 63(2):399-401. PubMed ID: 25688620 [No Abstract] [Full Text] [Related]
6. Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy? Simpson PJ; Ooi C; Chong J; Smith A; Baldey A; Staples M; Woods S J Gastrointest Surg; 2009 Mar; 13(3):432-7. PubMed ID: 18979143 [TBL] [Abstract][Full Text] [Related]
7. Impact of sleep disorders in Japanese patients with functional dyspepsia (FD): nizatidine improves clinical symptoms, gastric emptying and sleep disorders in FD patients. Futagami S; Yamawaki H; Izumi N; Shimpuku M; Kodaka Y; Wakabayashi T; Nagoya H; Shindo T; Kawagoe T; Gudis K; Itoh T; Sakamoto C J Gastroenterol Hepatol; 2013 Aug; 28(8):1314-20. PubMed ID: 23611167 [TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients. Gil RA; Hwynn N; Fabian T; Joseph S; Fernandez HH Parkinsonism Relat Disord; 2011 May; 17(4):285-7. PubMed ID: 21296606 [TBL] [Abstract][Full Text] [Related]
9. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. Orenstein SR; Gremse DA; Pantaleon CD; Kling DF; Rotenberg KS Clin Ther; 2005 Apr; 27(4):472-83. PubMed ID: 15922820 [TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled study of the effectiveness and safety of nizatidine in the prevention of postprandial heartburn. Spiegel JE; Thoden WR; Pappas K; Fratarcangelo P; Furey SA Arch Intern Med; 1997 Jul; 157(14):1594-9. PubMed ID: 9236562 [TBL] [Abstract][Full Text] [Related]
12. Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson's disease. Triadafilopoulos G; Gandhy R; Barlow C Parkinsonism Relat Disord; 2017 Nov; 44():33-37. PubMed ID: 28847681 [TBL] [Abstract][Full Text] [Related]
13. Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjögren's syndrome. Kasama T; Shiozawa F; Isozaki T; Matsunawa M; Wakabayashi K; Odai T; Yajima N; Miwa Y; Negishi M; Ide H Mod Rheumatol; 2008; 18(5):455-9. PubMed ID: 18478182 [TBL] [Abstract][Full Text] [Related]
14. Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis. Hamamoto N; Hashimoto T; Adachi K; Hirakawa K; Ishihara S; Inoue H; Taniura H; Niigaki M; Sato S; Kushiyama Y; Suetsugu H; Miyake T; Kinoshita Y J Gastroenterol Hepatol; 2005 Feb; 20(2):281-6. PubMed ID: 15683433 [TBL] [Abstract][Full Text] [Related]
16. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Ejskjaer N; Wo JM; Esfandyari T; Mazen Jamal M; Dimcevski G; Tarnow L; Malik RA; Hellström PM; Mondou E; Quinn J; Rousseau F; McCallum RW Neurogastroenterol Motil; 2013 Feb; 25(2):e140-50. PubMed ID: 23279217 [TBL] [Abstract][Full Text] [Related]
17. Double blind controlled trial of effect of cisapride on gastric emptying in diabetics. Dutta U; Padhy AK; Ahuja V; Sharma MP Trop Gastroenterol; 1999; 20(3):116-9. PubMed ID: 10695417 [TBL] [Abstract][Full Text] [Related]
18. [Maintenance therapy of mild form of GERD by H2 receptor antagonists]. Kurosawa S Nihon Rinsho; 2000 Sep; 58(9):1859-64. PubMed ID: 11004816 [TBL] [Abstract][Full Text] [Related]
19. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Armstrong D; Paré P; Pericak D; Pyzyk M; Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354 [TBL] [Abstract][Full Text] [Related]
20. Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs. Lin TM; Evans DC; Warrick MW; Pioch RP J Pharmacol Exp Ther; 1986 Nov; 239(2):406-10. PubMed ID: 2877081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]